Company Update: Merck & Co Inc (NYSE:MRK) – Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress
April 21, 2015 at 08:30 AM EDT
[Business Wire] – Merck , known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including . . . → Read More: Company Update: Merck & Co Inc (NYSE:MRK) – Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress Similar Articles: Stock Update (NYSE:MRK): Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone Market Update (NYSE:MRK): Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Present at the 35th Annual Cowen Health Care Conference